慢性可诱导性荨麻疹的治疗进展

doi:10.35541/cjd.20210677

中华皮肤科杂志 ›› 2021, Vol. 54 ›› Issue (12): 1110-1113.doi: 10.35541/cjd.20210677

慢性可诱导性荨麻疹的治疗进展

陈奇权宋志强

陆军军医大学西南医院皮肤科，重庆 400038

收稿日期:2021-09-15 修回日期:2021-10-11 发布日期:2021-12-01
通讯作者: 宋志强 E-mail:drsongzq@qq.com
基金资助:
国家自然科学基金（82003359）

Treatment of chronic inducible urticaria

Chen Qiquan, Song Zhiqiang

Department of Dermatology, Southwest Hospital, Army Medical University, Chongqing 400038, China

Received:2021-09-15 Revised:2021-10-11 Published:2021-12-01
Contact: Song Zhiqiang E-mail:drsongzq@qq.com
Supported by:
National Natural Science Foundation of China（82003359）

摘要/Abstract

摘要： 【摘要】慢性可诱导性荨麻疹（CIndU）的发病机制目前尚未完全清楚，仅仅靠针对诱因的规避常常无法达到满意的症状控制效果。近年来国内外在CIndU的治疗方面取得一定进展，如传统的抗组胺药、非抗组胺药、生物制剂及小分子靶向药等药物治疗，以及诱因脱敏治疗等物理治疗等，本文对这些进展进行全面系统的梳理和总结。

关键词: 荨麻疹, 治疗, 组胺拮抗药, 生物制剂, 慢性可诱导性荨麻疹, 物理性荨麻疹

Abstract: 【Abstract】 At present, the pathogenesis of chronic inducible urticaria （CIndU） is not completely clear, and it is often difficult to achieve satisfactory symptom control only by avoiding triggers. In recent years, some progress has been made in the treatment of CIndU in China and other countries, such as traditional antihistamines, non-antihistamines, biological agents, small-molecule targeted drugs and other drug treatments, as well as physical therapies such as trigger-point desensitization therapy. This review comprehensively and systematically outlines and summarizes relevant progress.

Key words: Urticaria, Therapy, Histamine antagonists, Biological agents, Chronic inducible urticaria, Physical urticaria

陈奇权宋志强. 慢性可诱导性荨麻疹的治疗进展[J]. 中华皮肤科杂志, 2021,54(12):1110-1113. doi:10.35541/cjd.20210677

Chen Qiquan, Song Zhiqiang. Treatment of chronic inducible urticaria[J]. Chinese Journal of Dermatology, 2021, 54(12): 1110-1113.doi:10.35541/cjd.20210677

参考文献 37

［1］	中华医学会皮肤性病学分会荨麻疹研究中心. 中国荨麻疹诊疗指南（2018版）［J］. 中华皮肤科杂志, 2019,52（1）:1⁃5. doi: 10.3760/cma.j.issn.0412⁃4030.2019.01.001.
［2］	Maurer M, Fluhr JW, Khan DA. How to approach chronic inducible urticaria［J］. J Allergy Clin Immunol Pract, 2018,6（4）:1119⁃1130. doi: 10.1016/j.jaip.2018.03.007.
［3］	Maurer M, Hawro T, Krause K, et al. Diagnosis and treatment of chronic inducible urticaria［J］. Allergy, 2019,74（12）:2550⁃2553. doi: 10.1111/all.13878.
［4］	Kocatürk E, Can PK, Akbas PE, et al. Management of chronic inducible urticaria according to the guidelines: a prospective controlled study［J］. J Dermatol Sci, 2017,87（1）:60⁃69. doi: 10. 1016/j.jdermsci.2017.02.283.
［5］	Pereira A, Motta AA, Kalil J, et al. Chronic inducible urticaria: confirmation through challenge tests and response to treatment［J］. Einstein （Sao Paulo）, 2020,18:eAO5175. doi: 10.31744/einstein_journal/2020ao5175.
［6］	Fukunaga A, Washio K, Hatakeyama M, et al. Cholinergic urticaria: epidemiology, physiopathology, new categorization, and management［J］. Clin Auton Res, 2018,28（1）:103⁃113. doi: 10. 1007/s10286⁃017⁃0418⁃6.
［7］	Maltseva N, Borzova E, Fomina D, et al. Cold urticaria ⁃ what we know and what we do not know［J］. Allergy, 2021,76（4）:1077⁃1094. doi: 10.1111/all.14674.
［8］	Pezzolo E, Peroni A, Gisondi P, et al. Heat urticaria: a revision of published cases with an update on classification and management［J］. Br J Dermatol, 2016,175（3）:473⁃478. doi: 10.1111/bjd. 14543.
［9］	Dressler C, Werner RN, Eisert L, et al. Chronic inducible urticaria: a systematic review of treatment options［J］. J Allergy Clin Immunol, 2018,141（5）:1726⁃1734. doi: 10.1016/j.jaci.2018. 01.031.
［10］	Cassano N, Mastrandrea V, Vestita M, et al. An overview of delayed pressure urticaria with special emphasis on pathogenesis and treatment［J］. Dermatol Ther, 2009,22 Suppl 1:S22⁃S26. doi: 10.1111/j.1529⁃8019.2009.01268.x.
［11］	Morgado⁃Carrasco D, Fustà⁃Novell X, Podlipnik S, et al. Clinical and photobiological response in eight patients with solar urticaria under treatment with omalizumab, and review of the literature［J］. Photodermatol Photoimmunol Photomed, 2018,34（3）:194⁃199. doi: 10.1111/phpp.12370.
［12］	Kulthanan K, Ungprasert P, Tuchinda P, et al. Symptomatic dermographism: a systematic review of treatment options［J］. J Allergy Clin Immunol Pract, 2020,8（9）:3141⁃3161. doi: 10. 1016/j.jaip.2020.05.016.
［13］	Wang F, Zhao YK, Luo ZY, et al. Aquagenic cutaneous disorders［J］. J Dtsch Dermatol Ges, 2017,15（6）:602⁃608. doi: 10.1111/ddg.13234.
［14］	Magerl M, Altrichter S, Borzova E, et al. The definition, diagnostic testing, and management of chronic inducible urticarias ⁃ The EAACI/GA（2） LEN/EDF/UNEV consensus recommendations 2016 update and revision［J］. Allergy, 2016,71（6）:780⁃802. doi: 10.1111/all.12884.
［15］	Kozaru T, Fukunaga A, Taguchi K, et al. Rapid desensitization with autologous sweat in cholinergic urticaria［J］. Allergol Int, 2011,60（3）:277⁃281. doi: 10.2332/allergolint.10⁃OA⁃0269.
［16］	Kring Tannert L, Stahl Skov P, Bjerremann Jensen L, et al. Cold urticaria patients exhibit normal skin levels of functional mast cells and histamine after tolerance induction［J］. Dermatology, 2012,224（2）:101⁃105. doi: 10.1159/000336572.
［17］	Pezzolo E, Peroni A, Gisondi P, et al. Heat urticaria: a revision of published cases with an update on classification and management［J］. Br J Dermatol, 2016,175（3）:473⁃478. doi: 10.1111/bjd. 14543.
［18］	Aguilera P. Inducing light tolerance with narrowband UV⁃B therapy in solar urticaria［J］. Actas Dermosifiliogr （Engl Ed）, 2018,109（10）:853. doi: 10.1016/j.ad.2018.06.009.
［19］	Takahagi S, Tanaka A, Hide M. Sweat allergy［J］. Allergol Int, 2018,67（4）:435⁃441. doi: 10.1016/j.alit.2018.07.002.
［20］	Beissert S, Ständer H, Schwarz T. UVA rush hardening for the treatment of solar urticaria［J］. J Am Acad Dermatol, 2000,42（6）:1030⁃1032. doi: 10.1016/s0190⁃9622（00）90299⁃8.
［21］	Gaebelein⁃Wissing N, Ellenbogen E, Lehmann P. Solar urticaria: clinic, diagnostic, course and therapy management in 27 patients［J］. J Dtsch Dermatol Ges, 2020,18（11）:1261⁃1268. doi: 10. 1111/ddg.14309.
［22］	Borzova E, Rutherford A, Konstantinou GN, et al. Narrowband ultraviolet B phototherapy is beneficial in antihistamine⁃resistant symptomatic dermographism: a pilot study［J］. J Am Acad Dermatol, 2008,59（5）:752⁃757. doi: 10.1016/j.jaad.2008. 07.016.
［23］	Siiskonen H, Smorodchenko A, Krause K, et al. Ultraviolet radiation and skin mast cells: effects, mechanisms and relevance for skin diseases［J］. Exp Dermatol, 2018,27（1）:3⁃8. doi: 10. 1111/exd.13402.
［24］	Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria［J］. Allergy, 2018,73（7）:1393⁃1414. doi: 10.1111/all.13397.
［25］	宋晓婷, 刘擘, 陈玉迪, 等. 奥马珠单抗治疗27例人工荨麻疹回顾分析［J］. 中华皮肤科杂志, 2021,54（12）:1092⁃1096. doi: 10.35541/cjd.20210473.
［26］	Boyce JA. Successful treatment of cold⁃induced urticaria/anaphylaxis with anti⁃IgE［J］. J Allergy Clin Immunol, 2006,117（6）:1415⁃1418. doi: 10.1016/j.jaci.2006.04.003.
［27］	Maurer M, Metz M, Brehler R, et al. Omalizumab treatment in patients with chronic inducible urticaria: a systematic review of published evidence［J］. J Allergy Clin Immunol, 2018,141（2）:638⁃649. doi: 10.1016/j.jaci.2017.06.032.
［28］	Pressler A, Grosber M, Halle M, et al. Failure of omalizumab and successful control with ketotifen in a patient with vibratory angio⁃oedema［J］. Clin Exp Dermatol, 2013,38（2）:151⁃153. doi: 10. 1111/j.1365⁃2230.2012.04430.x.
［29］	Can PK, Salman A, Hoşgören⁃Tekin S, et al. Effectiveness of omalizumab in patients with chronic inducible urticaria: real⁃life experience from two UCARE centres［J］. J Eur Acad Dermatol Venereol, 2021,35（10）:e679⁃e682. doi: 10.1111/jdv.17385.
［30］	Fialek M, Dezoteux F, Le Moing A, et al. Omalizumab in chronic inducible urticaria: a retrospective, real⁃life study［J］. Ann Dermatol Venereol, 2021:S0151⁃9638（21）00063⁃6. doi: 10. 1016/j.annder.2021.04.010.
［31］	Bodar EJ, Simon A, de Visser M, et al. Complete remission of severe idiopathic cold urticaria on interleukin⁃1 receptor antagonist （anakinra）［J］. Neth J Med, 2009,67（9）:302⁃305.
［32］	Gualdi G, Monari P, Rossi MT, et al. Successful treatment of systemic cold contact urticaria with etanercept in a patient with psoriasis［J］. Br J Dermatol, 2012,166（6）:1373⁃1374. doi: 10. 1111/j.1365⁃2133.2011.10797.x.
［33］	Magerl M, Philipp S, Manasterski M, et al. Successful treatment of delayed pressure urticaria with anti⁃TNF⁃alpha［J］. J Allergy Clin Immunol, 2007,119（3）:752⁃754. doi: 10.1016/j.jaci.2006. 12.658.
［34］	Ferrucci S, Benzecry V, Berti E, et al. Rapid disappearance of both severe atopic dermatitis and cold urticaria following dupilumab treatment［J］. Clin Exp Dermatol, 2020,45（3）:345⁃346. doi: 10.1111/ced.14081.
［35］	Maurer M, Altrichter S, Metz M, et al. Benefit from reslizumab treatment in a patient with chronic spontaneous urticaria and cold urticaria［J］. J Eur Acad Dermatol Venereol, 2018,32（3）:e112⁃e113. doi: 10.1111/jdv.14594.
［36］	Bergmann KC, Altrichter S, Maurer M. Benefit of benralizumab treatment in a patient with chronic symptomatic dermographism［J］. J Eur Acad Dermatol Venereol, 2019,33（11）:e413⁃e415. doi: 10.1111/jdv.15720.
［37］	Dickson MC, Walker A, Grattan C, et al. Effects of a topical treatment with spleen tyrosine kinase inhibitor in healthy subjects and patients with cold urticaria or chronic spontaneous urticaria: results of a phase 1a/b randomised double⁃blind placebo⁃controlled study［J］. Br J Clin Pharmacol, 2021 ［2021⁃09⁃01］. https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bcp. 14923. doi: 10.1111/bcp.14923.

[1]	侯晓媛吴南辉徐明圆刘业强. JAK抑制剂巴瑞替尼治疗环状肉芽肿1例[J]. 中华皮肤科杂志, 2024, 57(5): 461-462.
[2]	《乳房外Paget病诊治专家共识（版）》编写委员会专家组. [开放获取] 乳房外Paget病诊治专家共识（2024版）[J]. 中华皮肤科杂志, 2024, 57(5): 400-408.
[3]	中国医师协会皮肤科医师分会. [开放获取] 慢性瘙痒管理指南（2024版）[J]. 中华皮肤科杂志, 2024, 57(5): 387-399.
[4]	中国“一带一路”皮肤病专病联盟分枝杆菌病研究联盟中国麻风防治协会皮肤性病检验与诊断分会. [开放获取] 中国皮肤结核临床诊疗专家共识（2024版）[J]. 中华皮肤科杂志, 2024, 57(5): 426-434.
[5]	中国医师协会皮肤科医师分会中国中西医结合学会皮肤性病学分会. 红皮病型银屑病诊疗中国专家共识（2024版）[J]. 中华皮肤科杂志, 2024, 57(5): 409-417.
[6]	中国中西医结合学会皮肤性病学分会真菌学组中国耐药皮肤癣菌病诊治与防控工作组. [开放获取] 中国耐药皮肤癣菌感染诊治与防控专家共识（2024版）[J]. 中华皮肤科杂志, 2024, 57(5): 418-425.
[7]	陆佳维鲁严. 肿瘤坏死因子α抑制剂及其他生物制剂相关矛盾性银屑病的临床研究进展[J]. 中华皮肤科杂志, 2024, 57(5): 479-482.
[8]	郭澜晋红中. 治疗瘙痒的小分子/生物制剂药物研究进展[J]. 中华皮肤科杂志, 2024, 57(5): 475-478.
[9]	刘祎曲莹雷文知刘晓刚潘炜华张超. 食盐封包法治疗化脓性肉芽肿25例临床观察[J]. 中华皮肤科杂志, 2024, 0(4): 20230553-e20230553.
[10]	鞠强李嘉祺. [开放获取] 寻常痤疮再认识：从发病机制到治疗策略[J]. 中华皮肤科杂志, 2024, 57(4): 289-294.
[11]	张迪敏曹成周妙妮盛安琪林福全许爱娥. 复方倍他米松注射液联合治疗后进展期非节段型白癜风稳定率及影响因素分析[J]. 中华皮肤科杂志, 2024, 57(4): 350-354.
[12]	周甜甜吴雪歌杨欢方晓蒋金秋陈静思罗晓燕王华. 儿童慢性自发性荨麻疹病因及严重程度相关因素分析[J]. 中华皮肤科杂志, 2024, 57(4): 324-330.
[13]	田静邓思思宋志强. 特应性与非特应性结节性痒疹患者临床特征比较[J]. 中华皮肤科杂志, 2024, 57(4): 331-337.
[14]	岳淑珍树叶罗鸯鸯李珂瑶张圆圆汤建萍韦祝. 奥马珠单抗治疗儿童慢性荨麻疹的疗效和安全性回顾研究[J]. 中华皮肤科杂志, 2024, 57(4): 354-358.
[15]	葛新红马迎东焦亚宁刘玲玲周镁紫薇李博文. 532 nm皮秒激光治疗面部早期脂溢性角化病的疗效和安全性分析[J]. 中华皮肤科杂志, 2024, 57(4): 359-362.

慢性可诱导性荨麻疹的治疗进展

Treatment of chronic inducible urticaria

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 37

相关文章 15

Metrics

本文评价

推荐阅读 10